Forbes  Apr 10  Comment 
In just 14 years, the International Automobile Exhibition in Beijing and Shanghai has become one of the premier auto shows in the world.
Benzinga  Mar 3  Comment 
Below are the top scientific & technical instruments stocks on the NYSE in terms of return on equity. The trailing-twelve-month return on equity at Mettler-Toledo International (NYSE: MTD) is 34.74%. Mettler-Toledo's revenue for the same period...
Benzinga  Feb 11  Comment 
Analysts at Mizuho Securities initiated coverage on shares of OncoMed (NASDAQ: OMED) with a “buy” rating. The target price for OncoMed is set to $45. OncoMed's shares closed at $31.47 yesterday. Analysts at Drexel Hamilton initiated...
StreetInsider.com  Feb 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/UBS+Upgrades+Mettler-Toledo+%28MTD%29+to+Buy/9138142.html for the full story.
Benzinga  Feb 6  Comment 
In a report published Thursday, Morgan Stanley analyst Daniel Brennan reiterated an Overweight rating and $279.00 price target on Mettler-Toledo International (NYSE: MTD). In the report, Morgan Stanley noted, “Q4 revenues at 3% growth...
TheStreet.com  Feb 6  Comment 
NEW YORK (TheStreet) -- CHANGE IN RATINGS Arlington Asset was downgraded to hold at TheStreet Ratings.Akamai was upgraded at Credit Suisse to neutral from underperform. Twelve-month price target is $47.50. Company should continue to deliver...
SeekingAlpha  Feb 6  Comment 
Mettler-Toledo International (MTD) Q4 2013 Earnings Call February 05, 2014 5:00 pm ET Executives Mary T. Finnegan - Head of Investor Relations and Treasurer Olivier A. Filliol - Chief Executive Officer, President and Director ...
SeekingAlpha  Feb 4  Comment 
By Stephen Simpson, CFA: The last year has not been all that great for the shares of European specialty instrumentation and controls company Spectris (OTCPK:SEPJY) (SXS.L), though the stock has done pretty well compared to peer group members like...
Forbes  Jan 8  Comment 
Managing The Dragon (MTD) makes its predictions for 2014.
Forbes  Dec 31  Comment 
Managing The Dragon (MTD) looks back and rates its 2013 predictions for China.


Mettler-Toldedo International develops precision instruments primarily for the life science industry (pharmaceutical and biotech companies, as well as independent research organizations); food and beverage producers; food retailers, and chemical, specialty chemicals and cosmetics companies. It focuses primarily on laboratory and industrial instruments. The company sells products primarily in Europe, the Americas, and Asia. Its global presence represents strong growth opportunities, however their markets can be unpredictable. Also due to the large capital expenditure of its instruments MTD's revenues experience seasonality and can fluctuate according to capital spending patterns of customers, tending to be larger in the fourth quarter of each year.[1]

Business Growth

For 2010 the company reported net sales of $1,968 million, an increase of 14% over 2009. The increase in sales was attributed to improved global economic conditions and deferral of product replacements by customers during 2009.[1]

Trends and Forces

Economic conditions in emerging markets represent growth opportunities, but can be unpredictable

Although the majority of MTD's sales are in developed countries it is quickly growing sales in emerging markets. For example, in 2010 sales in China accounted for just under $300 million of yearly sales. In addition to China the company has sales in other emerging markets of Asia, Latin America, and Eastern Europe. Though these countries represent strong growth opportunities they can be unpredictable and with varying amount of currency risk and local legal and regulatory requirements.[1]

MTD's revenues can fluctuate according to capital spending patterns of customers

MTD's customers often stock up on lab consumables and equipment at the end of the year, when funding is abundant (for example, NIH funding is distributed to labs towards the end of the calendar year). MTD's revenues thus fluctuate throughout the year and are strongest in the last quarter of the calendar year. NIH funding is not completely stable, either - economic pressures may result in a stagnation of NIH funding, which has been growing at 2-3% in the past few years, but is not expected to increase in the near future. MTD's customers from academic and government research labs are directly affected by the limitations of NIH grant funding; a lack of funding results in fewer laboratory product and equipment purchases and adversely affects MTD's sales revenues.[1]



  1. 1.0 1.1 1.2 1.3 Mettler-Toledo International 2011 10k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki